Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
A Netflix documentary about a British Asian catfishing victim has sparked calls for legal reform to tackle catfishing and online deception.
Released on Thursday (16), Sweet Bobby: My Catfish Nightmare tells the true story of Kirat Assi, who was deceived in a prolonged catfishing scheme.
Catfishing is an online scam where someone pretends to be someone else to fool others into thinking they are friends or in a romantic relationship.
The film, directed by Lyttanya Shannon, created in partnership with Tortoise Media and inspired by its popular podcast of the same name, follows Assi as she narrates her story in a mostly chronological, first-person format.
Reviewers rate the documentary as average 'paired with familiar sentiments about moving forward after enduring unimaginable psychological manipulation'.
Over the course of eight years, Assi believed she was in contact with a man named Bobby Jandu, only to discover that the person behind the deception was actually her cousin, Simran Bhogal.
It all began in 2010 when Assi, a London-based radio presenter, received a Facebook friend request from Jandu, a man she thought she shared mutual connections with. Their friendship grew through regular online exchanges, and he confided in her about his personal struggles, including a difficult marriage.
Over the years, their relationship deepened, but they never met in person. Instead, Jandu's life seemed to become more and more complicated. He claimed to have been shot while in Kenya, supposedly placing him in witness protection.
As their connection continued online, his numerous health crises, including a stroke and heart attack, were always corroborated by others who reached out to Assi, convincing her that his situations were real.
The emotional manipulation escalated to the point where her mental health suffered. She became overwhelmed by stress and was signed off work.
Eventually, she grew suspicious, especially after failed attempts to meet him in person. In 2018, her doubts led her to hire a private investigator who traced him to an address in Brighton.
When she arrived at the house, she was confronted with the truth: Jandu didn’t exist, and the man she had been corresponding with had no idea who she was.
The shocking twist was revealed when Kirat confronted her cousin, Bhogal, who confessed to having orchestrated the entire deception. She had been impersonating Jandu for years, manipulating her emotions and fabricating elaborate lies.
This betrayal left Assi devastated, not only because of the emotional toll but also because the catfishing had come from someone she considered family.
In 2020, Kirat took legal action against Bhogal, winning a civil case for harassment, misuse of private information, and data breaches. Despite the legal victory, Bhogal has remained largely out of the public eye, refusing to participate in the Netflix documentary based on the Sweet Bobby podcast. She maintains that the matter is a private family issue, stemming from events that began when she was a schoolgirl.
Assi, meanwhile, has shared her story in the hope that it might help others recognise the dangers of online manipulation and speak out if they feel they aren’t being believed.
“What is important to understand about me and other victims of catfishing is that we need to be allowed to be happy, but at the same time it doesn’t mean that we don’t still suffer. My suffering is personal. Suffering is being vulnerable and I don’t want to share that with everybody. I don’t want to be judged for being happy after having gone through something awful. Victims deserve happiness," she told the Times.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.